Truist Financial Forecasts Strong Price Appreciation for Privia Health Group (NASDAQ:PRVA) Stock

Privia Health Group (NASDAQ:PRVA) had its price target increased by equities research analysts at Truist Financial from $27.00 to $28.00 in a research note issued to investors on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock. Truist Financial’s price objective suggests a potential upside of 22.83% from the stock’s previous close.

Several other analysts also recently weighed in on the company. JMP Securities set a $29.00 price target on Privia Health Group in a research note on Friday, February 28th. Piper Sandler upped their price target on Privia Health Group from $25.00 to $40.00 and gave the company an “overweight” rating in a research report on Friday, February 28th. Canaccord Genuity Group increased their price objective on Privia Health Group from $29.00 to $30.00 and gave the stock a “buy” rating in a research report on Friday, February 28th. Stephens reiterated an “overweight” rating and issued a $26.00 price objective on shares of Privia Health Group in a research report on Thursday, January 2nd. Finally, Macquarie assumed coverage on Privia Health Group in a research report on Monday, December 16th. They issued an “outperform” rating and a $25.00 price objective for the company. One analyst has rated the stock with a hold rating, thirteen have issued a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Privia Health Group presently has a consensus rating of “Buy” and a consensus target price of $26.73.

Privia Health Group Trading Down 1.1 %

PRVA opened at $22.80 on Thursday. The firm has a market cap of $2.77 billion, a price-to-earnings ratio of 227.97, a PEG ratio of 3.47 and a beta of 0.88. Privia Health Group has a 12 month low of $15.92 and a 12 month high of $26.04. The stock has a fifty day moving average price of $23.73 and a 200-day moving average price of $21.41.

Insiders Place Their Bets

In other Privia Health Group news, CFO David Mountcastle sold 5,630 shares of the firm’s stock in a transaction dated Wednesday, April 2nd. The stock was sold at an average price of $22.38, for a total transaction of $125,999.40. Following the transaction, the chief financial officer now owns 179,676 shares of the company’s stock, valued at approximately $4,021,148.88. This trade represents a 3.04 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 14.20% of the stock is currently owned by insiders.

Institutional Trading of Privia Health Group

Institutional investors have recently made changes to their positions in the stock. XTX Topco Ltd acquired a new stake in shares of Privia Health Group in the third quarter valued at approximately $182,000. Barclays PLC grew its position in Privia Health Group by 240.3% in the 3rd quarter. Barclays PLC now owns 224,018 shares of the company’s stock worth $4,079,000 after purchasing an additional 158,188 shares during the last quarter. Geode Capital Management LLC boosted its position in Privia Health Group by 1.0% in the third quarter. Geode Capital Management LLC now owns 2,415,022 shares of the company’s stock valued at $43,986,000 after buying an additional 23,178 shares in the last quarter. Neo Ivy Capital Management bought a new position in shares of Privia Health Group in the third quarter worth about $66,000. Finally, Virtu Financial LLC bought a new stake in shares of Privia Health Group during the third quarter worth approximately $263,000. 94.48% of the stock is owned by hedge funds and other institutional investors.

About Privia Health Group

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.